Latest News for: anal

Edit

Teacher banned after shocking classroom comments and 'anal copulation' claims

The Mirror 07 Jan 2026
Patrick Lawler, who taught in Northumberland and Bristol, has been banned from the classroom after expressing radical views and making shocking remarks to children ... .
Edit

Incyte Japan Announces Approval of Zynyz� (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer

Business Wire 22 Dec 2025
TOKYO--(BUSINESS WIRE)---- $INCY--Incyte Japan Announces Approval of Zynyz� (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer ... .
Edit

Reference 4 - Niazi SK. Contradicting rulings of the US patent office on double patenting jeopardize the generic and biosimilar drugs. Pharm Pat Anal. 2025;13(4–6):95–103. doi:10.1080/20468954.2025.2459582 (The eRulemaking Program)

Public Technologies 05 Dec 2025
). Pharmaceutical Patent Analyst. ISSN. 2046-8954 (Print) 2046-8962 (Online) Journal homepage. https.//www.tandfonline.com/journals/ippa20 Contradicting rulings of the US patent office on double patenting jeopardize the generic and biosimilar drugs ... 716 ... .
Edit

How common is anal sex? Scientific facts about prevalence, pain, pleasure, and more

PsyPost 03 Dec 2025
They found that anal intercourse is commonly practiced among youth ... They termed these practices Anal Surfacing, Anal Shallowing, and Anal Pairing ... Anal Pairing describes anal touch that occurs simultaneously with other sexual acts.
Edit

South Africa: South Africa Has Relatively High Anal Cancer Rates, but We Rarely Screen for It

All Africa 17 Nov 2025
... both heightens the risk of anal cancers and their severity.
Edit

Vijay Sethupathi excited over son Surya’s debut film Phoenix, thanks director Anal Arasu

Hindustan Times 04 Nov 2025
The actor also expressed his gratitude to director Anal Arasu Master for giving Surya the opportunity ... The actor added that Anal Arasu Master narrated the story and asked if Surya could be a part of it ... Anal Arasu Master is the director of Phoenix.
Edit

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

PR Newswire 28 Oct 2025
Pelareorep plus atezolizumab achieves 30% ORR in second-line or later (≥2L) squamous cell anal carcinoma (SCAC) relative to 13.8% for the FDA-approved 2L treatment ... colorectal, and anal cancers.
Edit

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care (Form 6-K) (Oncolytics Biotech Inc)

Public Technologies 28 Oct 2025
) Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care ... 4.Pelareorep in combination with atezolizumab in 2nd line advanced and unresectable anal cancer patients; and.
Edit

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the ...

Canada Newswire 28 Oct 2025
"This is the most encouraging efficacy signal with a non-chemo regimen we have ever seen in anal cancer," said Jared Kelly, Chief Executive Officer of Oncolytics Biotech ... colorectal, and anal cancers.
×